HSBC Holdings
PTCT icon

HSBC Holdings’s PTC Therapeutics PTCT Stock Holding History

HSBC Holdings’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Sell
131,389
-95,670
-42% -$6.91M ﹤0.01% 946
2026
Q1 		$15.5M Buy
227,059
+214,931
+1,772% +$15.2M 0.01% 811
2025
Q4 		$926K Sell
12,128
-166,371
-93% -$12.1M ﹤0.01% 1979
2025
Q3 		$11M Buy
178,499
+148,489
+495% +$7.73M 0.01% 889
2025
Q2 		$1.47M Buy
30,010
+12,299
+69% +$584K ﹤0.01% 1618
2025
Q1 		$848K Buy
17,711
+1,243
+8% +$62K ﹤0.01% 1822
2024
Q4 		$749K Sell
16,468
-4,499
-21% -$193K ﹤0.01% 1953
2024
Q3 		$780K Buy
20,967
+2,049
+11% +$68.6K ﹤0.01% 1800
2024
Q2 		$567K Sell
18,918
-4,281
-18% -$139K ﹤0.01% 1915
2024
Q1 		$675K Buy
23,199
+5,913
+34% +$166K ﹤0.01% 1953
2023
Q4 		$475K Sell
17,286
-13,066
-43% -$299K ﹤0.01% 2068
2023
Q3 		$681K Sell
30,352
-8,715
-22% -$324K ﹤0.01% 1867
2023
Q2 		$1.58M Buy
39,067
+25,241
+183% +$1.24M ﹤0.01% 1538
2023
Q1 		$682K Sell
13,826
-31,740
-70% -$1.45M ﹤0.01% 1926
2022
Q4 		$1.69M Buy
45,566
+29,808
+189% +$1.24M ﹤0.01% 1755
2022
Q3 		$803K Sell
15,758
-8,389
-35% -$411K ﹤0.01% 1931
2022
Q2 		$969K Sell
24,147
-37,742
-61% -$1.32M ﹤0.01% 1942
2022
Q1 		$2.31M Sell
61,889
-8,875
-13% -$342K ﹤0.01% 1540
2021
Q4 		$2.85M Buy
70,764
+1,490
+2% +$57K ﹤0.01% 1523
2021
Q3 		$2.59M Buy
69,274
+41,941
+153% +$1.72M ﹤0.01% 1428
2021
Q2 		$1.16M Buy
27,333
+9,300
+52% +$398K ﹤0.01% 1691
2021
Q1 		$859K Buy
18,033
+10,963
+155% +$651K ﹤0.01% 1687
2020
Q4 		$435K Sell
7,070
-17,356
-71% -$1.02M ﹤0.01% 2293
2020
Q3 		$1.16M Buy
+24,426
New +$1.2M ﹤0.01% 1482
2020
Q2 		– Sell
-4,999
Closed -$221K – 2824
2020
Q1 		$221K Buy
4,999
+166
+3% +$8.36K ﹤0.01% 2238
2019
Q4 		$232K Buy
+4,833
New +$205K ﹤0.01% 2724
2018
Q3 		– Sell
-12,921
Closed -$436K – 2628
2018
Q2 		$436K Buy
+12,921
New +$403K ﹤0.01% 2123

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

HSBC Holdings's PTCT Position: Q2 2026 in Review

HSBC Holdings reduced its PTC Therapeutics (PTCT) stake by 42% in Q2 2026, selling an estimated $6.91M and leaving 131,389 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #946.

HSBC Holdings first reported a position in PTCT in Q2 2018 and has held it in 27 quarters since. The position peaked at $15.5M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • HSBC Holdings held 131,389 shares of PTC Therapeutics worth $10.8M as of Q2 2026.
  • HSBC Holdings sold 95,670 PTC Therapeutics shares in Q2 2026, an estimated $6.91M.
  • PTC Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #946 holding.
  • HSBC Holdings first reported a position in PTC Therapeutics in Q2 2018 and has held it in 27 quarters since.
  • HSBC Holdings's PTC Therapeutics position peaked at $15.5M in Q1 2026.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.